[Comparative analysis of arterial bioprostheses with various antithrombotic modification]

Area of Science:

• Vascular Surgery
• Biomaterials Science
• Pharmacology

Context:

• Infrainguinal arterial bypass grafting is crucial for limb salvage.
• Bioprosthetic materials are increasingly used, necessitating strategies to ensure long-term patency.
• Thrombosis and restenosis remain significant challenges in arterial bioprosthesis outcomes.

Purpose:

• To compare the remote patency of arterial bioprostheses modified with different antithrombotic agents.
• To evaluate the efficacy of low-molecular-weight heparin (LMWH) versus unfractionated heparin (UFH) in preventing complications.
• To assess the impact of antithrombotic modification on thrombosis and restenosis rates.

Summary:

• A study involving 133 patients compared arterial bioprostheses treated with UFH (Group I, n=91) versus LMWH (Group II, n=42).
• Thrombosis rates were significantly lower in the LMWH group (13.6%) compared to the UFH group (42.9%).
• Restenosis rates were also reduced with LMWH (7.3%) versus UFH (15.4%), indicating superior bioprosthesis patency.

Impact:

• Low-molecular-weight heparin (Clexane) demonstrates superior performance in maintaining arterial bioprosthesis patency.
• Antithrombotic modification with LMWH reduces the incidence of thrombosis and restenosis in infrainguinal bypasses.
• This finding supports the use of LMWH for optimizing outcomes in patients receiving arterial bioprostheses.